{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.6","upperLimit":"97.4","value":"89.4"},{"groupId":"OG001","lowerLimit":"78.3","upperLimit":"97","value":"87.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Primary tumor control is defined as the absence of primary tumor failure. Primary tumor failure (PTF) refers to the primary treated tumor after protocol therapy and corresponds to meeting following two criteria: 1) Increase in tumor dimension of 20% as defined above for local enlargement (LE); 2) The measurable tumor with criteria meeting LE should be avid on Positron Emission Tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, OR the measurable tumor should be biopsied confirming viable carcinoma. Marginal Failures (MF) and Involved Lobe Failures were also counted as PTF. The cumulative incidence method was used to estimate primary tumor control rate. The 90% confidence interval for local control was calculated using bootstrapping methods. Per the protocol, only the MTD dose level was to be analyzed. However, due to the quantity of patients enrolled on Dose Level 8 as well as safety concerns, Dose Level 8 was analyzed also.","dispersionType":"90% Confidence Interval","groups":[{"description":"SBRT 57.5 Gy\n\nSBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy","id":"OG000","title":"Level 8: 11.5 Gy/FX"},{"description":"SBRT 60.0 Gy\n\nSBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy","id":"OG001","title":"Level 9: 12.0 Gy/FX"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started study treatment","reportingStatus":"POSTED","timeFrame":"From start of SBRT to 2 years.","title":"(Phase II) Primary Tumor Control Rate at the Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}